Evidence map›Paper›PMID 39015503›Full record

ArticleFrontiers in oncology2024

Predicting immune checkpoint therapy response in three independent metastatic melanoma cohorts.

Leticia Szadai, Aron Bartha, Indira Pla Parada, Alexandra I T Lakatos, Dorottya M P Pál, Anna Sára Lengyel, Natália Pinto de Almeida, Ágnes Judit Jánosi, Fábio Nogueira, Beata Szeitz and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors.

Leticia SzadaiDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
Aron BarthaDepartment of Bioinformatics, Semmelweis University, Budapest, Hungary.
Indira Pla ParadaSection for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, Malmö, Sweden.
Alexandra I T LakatosHCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
Dorottya M P PálHCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
Anna Sára LengyelHCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
Natália Pinto de AlmeidaClinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Lund, Sweden.
Ágnes Judit JánosiDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
Fábio NogueiraChemistry Institute Federal, University of Rio de Janeiro, Rio de Janiero, Brazil.
Beata SzeitzDepartment of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Viktória DomaDepartment of Dermatology, Venereology, and Dermatooncology, Semmelweis University, Budapest, Hungary.
Nicole WoldmarClinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Lund, Sweden.
Jéssica GuedesSection for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, Malmö, Sweden.
Zsuzsanna UjfaludiDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Zoltán Gábor PahiDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Tibor PankotaiDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Yonghyo KimTherapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology (KRICT), Daejeon, Republic of Korea.
Balázs GyőrffyDepartment of Bioinformatics, Semmelweis University, Budapest, Hungary.
Bo BaldetorpDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Charlotte WelinderDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
A Marcell SzaszDepartment of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Lazaro BetancourtClinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Lund, Sweden.
Jeovanis GilClinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Lund, Sweden.
Roger AppelqvistClinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Lund, Sweden.
Ho Jeong KwonChemical Genomics Global Research Lab, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
Sarolta KárpátiDepartment of Dermatology, Venereology, and Dermatooncology, Semmelweis University, Budapest, Hungary.
Magdalena KurasClinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Lund, Sweden.
Jimmy Rodriguez MurilloDepartment of Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
István Balázs NémethDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
Johan MalmSection for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, Malmö, Sweden.
David FenyöDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, United States.
Krzysztof PawłowskiDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Peter HorvatovichAnalytical Biochemistry, Department of Pharmacy, University of Groningen, Groningen, Netherlands.
Elisabet WieslanderDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Lajos V KeményHCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
Gilberto DomontChemistry Institute Federal, University of Rio de Janeiro, Rio de Janiero, Brazil.
György Marko-Varga *Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Lund, Sweden.
Aniel Sanchez *Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, Malmö, Sweden.

Funding

Proteogenomic Data Analysis for Cancer Systems Biology and Clinical TranslationU24CA210972 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DING, LI, FENYO, DAVID · 2016 to 2020
$3.3M
NCI NIH HHS U24 CA210972
6 · The paper itself

Abstract

Introduction: While Immune checkpoint inhibition (ICI) therapy shows significant efficacy in metastatic melanoma, only about 50% respond, lacking reliable predictive methods. We introduce a panel of six proteins aimed at predicting response to ICI therapy. Methods: Evaluating previously reported proteins in two untreated melanoma cohorts, we used a published predictive model (EaSIeR score) to identify potential proteins distinguishing responders and non-responders. Results: Six proteins initially identified in the ICI cohort correlated with predicted response in the untreated cohort. Additionally, three proteins correlated with patient survival, both at the protein, and at the transcript levels, in an independent immunotherapy treated cohort. Discussion: Our study identifies predictive biomarkers across three melanoma cohorts, suggesting their use in therapeutic decision-making.

Indexed as

immunotherapyimmunotherapy responsemetastatic melanomanon-respondersproteomicsresponders

Identifiers

PMID39015503
PMCPMC11249723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.